A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients.
Mehrdokht MazdehShahriar Kargar MonhaserMohammad TaheriSoudeh Ghafouri-FardPublished in: Clinical and translational medicine (2019)
Treated patients experienced no relapse during the study period. Fingolimod is effective in reduction of EDSS score and number of relapses in Iranian MS patients.